AFFILIATIONS
1 Hematology, Hemostasis, Oncology and Cell Therapy, Hanover Medical School, Hanover, Germany, Institute of Immunology, Hanover Medical School, Hanover, Germany
2 Cluster of Excellence RESIST (EXC 2155), Hanover Medical School, Hanover, Germany, Department of Pediatric Pneumology, Allergology and Neonatology, Hanover Medical School, Hanover, Germany, Institute of Immunology, Hanover Medical School, Hanover, Germany
3 Institute of Immunology, Hanover Medical School, Hanover, Germany
4 University Medical Center and University Cancer Center Schleswig-Holstein Campus Lübeck, Department of Hematology and Oncology, Lübeck, Germany
5 University Hospital Halle, Halle/Saale, Halle, Germany
6 Medical Center - University of Freiburg, Faculty of Medicine, Department of Medicine I, Freiburg, Germany
7 Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
8 Frankfurt Institute of Clinical Cancer Research (IKF), Frankfurt, Germany
9 Charite Berlin, Department of Hematology, Oncology and Stem Cell Transplantation, Berlin, Germany
10 University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, Minden, Germany
11 University Medicine Greifswald, Internal Medicine C, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Greifswald, Germany
12 Frankfurt Institute of Clinical Cancer Research (IKF), Frankfurt, Germany
13 Frankfurt Institute of Clinical Cancer Research (IKF), Frankfurt, Germany
14 Frankfurt Institute of Clinical Cancer Research (IKF), Frankfurt, Germany
15 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
16 Hematology, Hemostasis, Oncology and Cell Therapy, Hanover Medical School, Hanover, Germany
17 University Medicine Greifswald, Internal Medicine C, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Greifswald, Germany
18 Hematology/Oncology, Jena University Hospital, Jena, Germany
19 Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
20 Institute of Immunology, Hanover Medical School, Hanover, Germany
21 Clinic for Hematology, Oncology and Immunology, St. Bernward Hospital, Hildesheim, Germany, Hematology, Hemostasis, Oncology and Cell Therapy, Hanover Medical School, Hanover, Germany
22 Hematology, Hemostasis, Oncology and Cell Therapy, Hanover Medical School, Hanover, Germany
23 Hematology, Hemostasis, Oncology and Cell Therapy, Hanover Medical School, Hanover, Germany
24 Hematology, Hemostasis, Oncology and Cell Therapy, Hanover Medical School, Hanover, Germany
ABSTRACT
Background
Among the chronic-phase myeloproliferative neoplasms (MPN), myelofibrosis (MF) follows the most aggressive clinical course, with a higher incidence of cytopenias and a substantially increased risk of disease progression. While JAK inhibitor (JAK-i) therapy has markedly improved symptoms and splenomegaly in MF, evidence for a disease-modifying effect is limited, and treatment options beyond JAK inhibition remain an unmet clinical need. Checkpoint inhibitors as monotherapy have demonstrated limited clinical efficacy in MF. However, within the FRACTION phase II study (NCT05393674, IKF-t051), nivolumab in combination with the selective JAK2 inhibitor fedratinib showed tolerability and clinical activity in patients with resistance or suboptimal response to prior JAK-i therapy. The immunological effects of this combination remain to be elucidated.
Aims
To comprehensively characterize longitudinal changes in circulating T-cell composition and functional phenotype during fedratinib-nivolumab combination treatment. To explore T-cell phenotypes associated with clinical response to the combination therapy.
Methods
Peripheral blood mononuclear cell samples from 30 patients enrolled in the FRACTION study were analyzed using 34-color spectral flow cytometry. According to MIPSS70 v2.0, 14 patients were classified as very high risk and 3 as high risk. Median treatment duration was 4.2 months. Treatment cycles were 4 weeks.
Overall, 71 samples were included for lineage proportion analyses and 74 samples for functional phenotyping. Major T-cell lineages, differentiated T-cell subsets and expression of 32 phenotypic markers were evaluated across baseline, Cycle 7 and end of therapy (EOT). Marker expression was quantified using asinh-transformed fluorescence intensity. Comparisons were performed between responders (R; complete/partial remission, clinical improvement or red blood cell transfusion independence per IWG-MRT) and non-responders (NR), as well as longitudinally throughout treatment. Healthy controls (HC) served as reference.
Results
Analysis across timepoints revealed consistent remodeling of circulating T-cell phenotypes, whereas baseline differences between R and NR were generally modest despite disease-associated alterations compared with HC. Among the 32 markers evaluated, PD-1 and CXCR5 exhibited the broadest treatment-associated modulation, each reaching significance in 9/19 analyzed T-cell populations. PD-1 expression decreased in γδ T-cells, regulatory T-cells, CD4 effector T-cells and CD8 central memory T-cells, while CXCR5 exhibited parallel reductions across regulatory, effector, memory and γδ T-cell subsets. Most changes emerged by Cycle 7 and partially recovered by EOT, suggesting dynamic rather than sustained immune remodeling. Additional modulation of activation and trafficking markers, including KLRB1 and L-selectin, further supported coordinated remodeling of circulating T-cell phenotypes during therapy.
Additionally, multiple comparisons identified response-associated phenotypic differences within T-cell subsets. CXCR5 and NKG2D expression were significantly lower in CD4 TEMRA-cells from R. Moreover, CD56 expression was reduced in Vγ9Vδ2 γδ T-cells from R. Inter-timepoint delta analyses further supported these findings and identified distinct treatment-associated dynamics between the response groups. The magnitude of PD-1 modulation in γδ T-cells from baseline to EOT was more pronounced in R, indicating divergent temporal remodeling despite largely shared overall treatment-associated phenotypic changes. Overall, we observed predominantly coordinated phenotypic changes, which were largely shared between R and NR, supporting their interpretation as pharmacodynamic effects of combined JAK2 inhibition and PD-1 blockade rather than response-specific biomarkers.
Conclusions
High-dimensional immune profiling identified coordinated remodeling of PD-1- and CXCR5-associated T-cell phenotypes as a reproducible pharmacodynamic signature of fedratinib–nivolumab combination therapy in MF patients. These changes span conventional, regulatory and γδ T-cell compartments and provide new insights into immune adaptation during combined JAK2 inhibition and PD-1 blockade. Complementary T-cell receptor repertoire profiling of flow cytometry-sorted CD4 conventional, CD8 and regulatory T-cell subsets is underway to provide an orthogonal assessment of the clonal dynamics accompanying these therapy-induced phenotypic changes.